FDA Greenlights Easier Path for Amblyopia Video Game Therapy
Published Date: 4/22/2026
Rule
Summary
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer, starting April 22, 2026. Device makers will benefit from simpler rules, saving time and money while keeping safety top-notch.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Faster Patient Access to Amblyopia Therapy
The FDA officially classified the digital therapy device for amblyopia as Class II (special controls), effective April 22, 2026. FDA says this classification will enhance patients' access to the treatment and provide a reasonable assurance of safety and effectiveness.
Lower Regulatory Hurdles for Device Makers
By classifying the device into Class II rather than automatic Class III, FDA says device makers face reduced regulatory burdens and can use this device as a predicate for future 510(k) submissions. FDA notes this De Novo classification can reduce time and cost for sponsors compared with premarket approval routes.
New Testing, Software, and Labeling Requirements
Manufacturers of digital therapy devices for amblyopia must meet specified special controls: clinical performance testing, software verification/validation and hazard analysis, non-clinical performance and display compatibility testing, and labeling that lists minimum hardware/OS requirements, validated display models, length of treatment supported by testing, and a summary of clinical testing; labeling comprehension testing is also required. The device remains subject to premarket notification under section 510(k).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-07860 — Medical Devices; Immunology and Microbiology Devices; Classification of the Alzheimer's Disease Pathology Assessment Test
The FDA is officially putting the Alzheimer's Disease Pathology Assessment Test into a safer, easier-to-manage category called Class II, starting April 22, 2026. This change helps patients get access to this important test faster by cutting down on red tape, while still making sure it’s safe and works well. Medical device makers will find it simpler and less costly to bring this test to market.
Next: 2026-07862 — Medical Devices; Anesthesiology Devices; Classification of the Device for Sleep Apnea Testing Based on Mandibular Movement
The FDA is officially putting sleep apnea testing devices that track jaw movement into a safer, easier-to-manage category called Class II. This change helps make sure the devices work well and are safe, while also making it simpler for new, helpful devices to reach patients faster. The new rules took effect on April 22, 2026, and could save companies time and money by cutting down on red tape.